Adagene Inc. (ADAG)
NASDAQ: ADAG · Real-Time Price · USD
3.660
-0.160 (-4.19%)
At close: May 4, 2026, 4:00 PM EDT
3.590
-0.070 (-1.91%)
After-hours: May 4, 2026, 7:47 PM EDT
Adagene Revenue
In the year 2025, Adagene had annual revenue of $7.67M with 7,332.75% growth. Adagene had revenue of $7.67M in the half year ending December 31, 2025, with 840.35% growth.
Revenue (ttm)
$7.67M
Revenue Growth
+7,332.75%
P/S Ratio
31.53
Revenue / Employee
$59,929
Employees
128
Market Cap
241.83M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 7.67M | 7.57M | 7,332.75% |
| Dec 31, 2024 | 103.20K | -18.01M | -99.43% |
| Dec 31, 2023 | 18.11M | 8.82M | 94.90% |
| Dec 31, 2022 | 9.29M | -882.58K | -8.67% |
| Dec 31, 2021 | 10.18M | 9.47M | 1,351.72% |
| Dec 31, 2020 | 700.91K | 220.91K | 46.02% |
| Dec 31, 2019 | 480.00K | -1.03M | -68.24% |
| Dec 31, 2018 | 1.51M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Heron Therapeutics | 154.90M |
| Arcturus Therapeutics Holdings | 82.03M |
| Compugen | 72.76M |
| Codexis | 70.39M |
| Alector | 21.05M |
| Sol-Gel Technologies | 19.39M |
| Artiva Biotherapeutics | 251.00K |
| SAB Biotherapeutics | 114.70K |
ADAG News
- 17 days ago - Adagene Presents Two Posters at AACR 2026 with New Data Highlighting Muzastotug's Potential as a Backbone Combination Therapy for Multiple Tumor Types - GlobeNewsWire
- 20 days ago - Adagene Adds Industry Veteran Peter Lebowitz to Scientific and Strategic Advisory Board - GlobeNewsWire
- 4 weeks ago - Adagene Announces Pricing of US$70.0 Million Public Offering of ADSs - GlobeNewsWire
- 4 weeks ago - Adagene Announces Clinical Collaboration with Incyte to Evaluate Muzastotug (ADG126) in Combination with Incyte's TGFßR2xPD-1 Bispecific Antibody (INCA33890) in Patients with Microsatellite Stable Colorectal Cancer (MSS CRC) - GlobeNewsWire
- 4 weeks ago - Updated Data from Phase 1b/2 Study of Muzastotug in Combination with KEYTRUDA® (pembrolizumab) in Late-line Patients with Microsatellite Stable Colorectal Cancer Demonstrate Improved Durability of Response - GlobeNewsWire
- 4 weeks ago - Adagene Reports Full Year 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 6 weeks ago - Adagene's Muzastotug (ADG126) to be Highlighted in Two Presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting in San Diego, CA - GlobeNewsWire
- 2 months ago - Adagene Transcript: Leerink Global Healthcare Conference 2026 - Transcripts